
According to the Zhitong Finance App, Shiyao Group (01093) announced results for the nine months ended September 30, 2026. The group obtained revenue of RMB 25.26 billion (same unit), an increase of 27.0% year on year; profit attributable to company owners was RMB 7.076 billion, up 101.5% year on year; profit per share was 62.14 points.
The proprietary pharmaceutical business recorded revenue of $21.648 billion (including license fee revenue of $6.268 billion) in the first nine months of 2026, an increase of 40.1% over the same period last year, mainly due to a sharp increase in license fee revenue and a steady increase in drug sales revenue.
In January 2026, the Group signed a strategic cooperation and licensing agreement with AstraZeneca for the development of innovative long-lasting peptide drugs (this agreement), and received a down payment of US$1.2 billion (this down payment) in May 2026 in accordance with the terms of the agreement. Of this down payment, US$840 million (equivalent to approximately $5.74 billion) was recognized as license fee revenue in the first nine months of 2026, which contributed significantly to the Group's revenue during the reporting period.
In the first nine months of 2026, the raw materials products business recorded sales revenue of 2,336 billion yuan, a decrease of 22.3% over the same period last year.
In the first nine months of 2026, sales revenue of vitamin C products was 1,451 billion yuan, down 18.9% from the same period last year, mainly affected by the decline in product sales prices; at the same time, the release of production capacity in the industry led to an increase in supply and increased competition, which led to a decrease in overall market prices. The Group will continue to consolidate product quality, optimize customer service, and steadily expand overseas sales channels to continuously increase market share.